Medical Advocates
 

Index of Select Abstracts. Posters, and Reports
 14th Conference on Retroviruses and
Opportunistic Infections
   
  Kaletra Data










 
Last Update:  February 27, 2007
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 
 
POSTER
The Steady-state Pharmacokinetics of Efavirenz and Lopinavir/Ritonavir in HIV-infected Persons
Requiring Hemodialysis: AIDS Clinical Trials Group Study A5177
S Gupta, S Rosenkranz, Y Segal, et al
 PDF Poster   Abstract
 
POSTER
Effect of Lopinavir and Ritonavir Dose Adjustments on the Pharmacokinetic Interaction between
LPV/RTV and Tipranavir
M Harris, S Ramirez, R Joy, et al
 PDF Poster    Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
Lack of Effect of Acid-reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir Tablet
C  Klein, Y L Chiu, Y Cai, et al 
PDF Poster    Abstract
 
POSTER
Final 48-Week Safety, Tolerability, and Efficacy of Capravirine + Lopinavir/ritonavir and
2 NRTI in Treatment-experienced Tablet
 P Hawley, J Hammond, R Tressler
 PDF Poster     Abstract
 
POSTER
Pharmacokinetics and Pharmacodynamics of Combined Use of Lopinavir/ritonavir and
Rosuvastatin in HIV-infected Patients
M Van Der Le, M Vogel, E Schippers, et al
 PDF Poster     Abstract
 
POSTER
Adequate Lopinavir Exposure Achieved with a Higher Dose during the Third Trimester of Pregnancy
M Mirochnick, A Stek, E Capparelli, et al
 PDF Poster     Abstract
 
Adequate Trough Lopinavir Levels with Standard Dosing in Pregnancy
 F Lyons, M Lechelt, V Magaya, et al
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Beneficial Pharmacokinetic Interaction between Atazanavir and Lopinavir/Ritonavir
P Pham, T Parsons, C Flexner, et al;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
The Effect of Lopinavir-Ritonavir ( LPVr) on Endothelial Function in Healthy Volunteers
J Grubb, A Dejam, J Voell,  et al
 Abstract
 
Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-infected Patients
J Kiser, M Carten, P Wolfe, et al
 Abstract
 
Therapeutic Drug Monitoring of Boosted Tipranavir with and without Combination to Lopinavi
r or Fosamprenavir
G Peytavin, A Marcelin, A Rouault,  et al
 Abstract
 
Peripheral and Visceral Fat Changes following a Treatment Switch to a Nonthymidine Analogue
or Nucleoside-sparing Regimen in Patients with Peripheral Lipoatrophy: 48-week Final Results
of ACTG A5110, a Prospective, Randomized Multicenter Clinical Trial
R Murpht, J Zhang, R Hafner, et al
Abstract
 
KLS Main Page   KLS Conference  Index  Home

13th Conference on Retroviruses and Opportunistic Infections
 Index of Kaletra Data